Clinical trial
A Phase IIa, Randomised, Double-blind, Placebo-controlled, Multicentre Study to Assess the Efficacy, Safety, and Tolerability of AZD4144 in Participants With Sepsis-associated Acute Kidney Injury (SERENIA)
NCT07215702 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase IIa, Randomised, Double-blind, Placebo-controlled, Multicentre Study to Assess the Efficacy, Safety, and Tolerability of AZD4144 in Participants With Sepsis-associated Acute Kidney Injury (SERENIA)
- Lead sponsor
- AstraZeneca
- Phase
- Phase 2
- Overall status
- Recruiting
- Start date
- February 10, 2026
- Completion date
- February 11, 2027
- Enrollment
- 124 (estimated)
- Sites
- 74
Conditions
As the registry lists them; a condition with its own page is linked.